Abstract The coronavirus disease 2019 (COVID‐19) pandemic is becoming one of the
largest global public health crises in modern history. The race for an effective drug to prevent …

The pandemic coronavirus disease 2019 (COVID-19), caused by the infection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading globally …

Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every …

Here, we advocate a highly favourable opportunity for the treatment of COVID-19 disease by
repurposing a long-serving medical agent with an excellent history of clinical use, namely …

Abstract Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in
mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low …

Heparin, an old but first-line anticoagulant, has been used over a century. It is a
heterogeneous, linear, highly sulfated, anionic glycosaminoglycan with a broad distribution …

2. Dianne K, Jennings I, Kitchen S, Walker I. Letter in response to article “Systematic review
of viscoelastic testing (TEG/Rotem) in obstetrics and recommendations from the women's …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of
variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute …

Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous
thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial …

Background and Purpose Currently, there are no licensed vaccines and limited antivirals for
the treatment of COVID‐19. Heparin (delivered systemically) is currently used to treat …